Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

about

Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery

P2860

Q57132503-BF22285A-701F-4B4E-991C-2BDB07320BDB

P2860

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

Item

http://www.wikidata.org/entity/Q38679229

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

@en

type

Item

label

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

@en

prefLabel

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

@en

P1476

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

@en

P2093

Alessia Bignucolo

http://www.w3.org/2001/XMLSchema#string

Elena De Mattia

http://www.w3.org/2001/XMLSchema#string

Erika Cecchin

http://www.w3.org/2001/XMLSchema#string

Giuseppe Toffoli

http://www.w3.org/2001/XMLSchema#string

Rossana Roncato

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Anti-angiogenic agents in metastatic colorectal cancer

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Liquid biopsies: genotyping circulating tumor DNA

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

P31

scholarly article

review article

P356

10.3390/IJMS18071522

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P5008

ScienceSource

P577

2017-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28708103

http://www.w3.org/2001/XMLSchema#string

P921

P932

5536012

http://www.w3.org/2001/XMLSchema#string

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

about

P2860

P2860

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932